Drug: Ofatumumab (Arzerra, Novartis)
Status: The therapy is now approved for extended treatment of patients who have achieved a complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL).
Significant Trial Data:
· A randomized, open-label trial compared ofatumumab with observation in 474 patients whose disease had a complete or partial response after at least two lines of prior